- Home
- ACRE vs ABSI Comparison
ACRE vs ABSI Comparison
Compare ACRE & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRE
- ABSI
- Stock Information
- Founded
- ACRE 2011
- ABSI 2011
- Country
- ACRE United States
- ABSI United States
- Employees
- ACRE N/A
- ABSI N/A
- Industry
- ACRE Real Estate Investment Trusts
- ABSI Biotechnology: Pharmaceutical Preparations
- Sector
- ACRE Real Estate
- ABSI Health Care
- Exchange
- ACRE Nasdaq
- ABSI Nasdaq
- Market Cap
- ACRE 388.6M
- ABSI 457.6M
- IPO Year
- ACRE 2012
- ABSI 2021
- Fundamental
- Price
- ACRE $7.16
- ABSI $2.55
- Analyst Decision
- ACRE Hold
- ABSI Strong Buy
- Analyst Count
- ACRE 7
- ABSI 6
- Target Price
- ACRE $7.10
- ABSI $8.67
- AVG Volume (30 Days)
- ACRE 442.3K
- ABSI 1.5M
- Earning Date
- ACRE 11-07-2024
- ABSI 11-12-2024
- Dividend Yield
- ACRE 13.95%
- ABSI N/A
- EPS Growth
- ACRE N/A
- ABSI N/A
- EPS
- ACRE N/A
- ABSI N/A
- Revenue
- ACRE $39,423,000.00
- ABSI $4,207,000.00
- Revenue This Year
- ACRE N/A
- ABSI $9.36
- Revenue Next Year
- ACRE $0.48
- ABSI $198.59
- P/E Ratio
- ACRE N/A
- ABSI N/A
- Revenue Growth
- ACRE N/A
- ABSI N/A
- 52 Week Low
- ACRE $6.25
- ABSI $1.35
- 52 Week High
- ACRE $11.24
- ABSI $6.72
- Technical
- Relative Strength Index (RSI)
- ACRE 60.42
- ABSI 24.46
- Support Level
- ACRE $6.86
- ABSI $2.45
- Resistance Level
- ACRE $7.15
- ABSI $4.47
- Average True Range (ATR)
- ACRE 0.24
- ABSI 0.28
- MACD
- ACRE 0.05
- ABSI -0.15
- Stochastic Oscillator
- ACRE 81.25
- ABSI 4.96
About ACRE Ares Commercial Real Estate Corporation
Ares Commercial Real Estate Corp is a specialty finance company and a Real Estate Investment Trust providing commercial real estate loans and related investments. It operates in one segment namely originating and managing a diversified portfolio of CRE debt-related investments. The group recognizes its revenues through the interest income it receives from loans.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.